
TriLink BioTechnologies® and Avantor® Partner to Expand Nucleic Acid Solutions in Europe
TriLink BioTechnologies a Maravai® LifeSciences company and a global leader in providing cutting-edge life science reagents and services, has announced a strategic partnership with Avantor a renowned global supplier of mission-critical products and services catering to customers in the life sciences and advanced technology industries. This collaboration aims to significantly expand the availability of TriLink’s innovative nucleic acid products to customers across Europe, the Middle East, and Africa (EMEA).

Enhancing Nucleic Acid Access in the EMEA Region
This distribution agreement between TriLink and Avantor is expected to streamline the ordering process, ensuring shorter lead times for European customers and enabling faster access to TriLink’s pioneering nucleic acid technologies. The life sciences industry in the EMEA region has witnessed rapid advancements, with an increasing demand for high-quality reagents and materials to facilitate research and therapeutic development. Through this partnership, TriLink will be able to efficiently meet this growing demand, enhancing scientific progress and accelerating breakthroughs in biotechnology.
For over 25 years, TriLink has established itself as a key player in nucleic acid product development and manufacturing, offering high-quality solutions for researchers and biopharmaceutical companies. With expertise in mRNA-based therapeutic innovations, the company has developed several industry-leading technologies that have contributed to groundbreaking advancements in RNA therapeutics, vaccines, and diagnostics.
Expanded Availability of TriLink’s Innovative Products
Under this agreement, Avantor will distribute TriLink’s extensive range of nucleic acid solutions throughout the EMEA region. Some of the core products that will now be more widely available include:
- CleanCap® Cap Analogs – These co-transcriptional mRNA caps have revolutionized the field of mRNA therapeutics by enhancing stability, translational efficiency, and overall efficacy.
- Catalog mRNAs – High-quality synthetic mRNAs designed for use in preclinical research and therapeutic development.
- Over 150 Modified and Unmodified Nucleotides – A comprehensive portfolio of nucleotides tailored for use in nucleic acid-based applications.
- High-Performance In Vitro Transcription (IVT) Enzymes – Including CleanScribe® RNA Polymerase, a highly effective enzyme for RNA synthesis and transcription.
In addition to direct distribution through Avantor, TriLink’s products will also be made available through VWR’s eCommerce platform, MarketSource, in the coming months. This digital marketplace will offer customers a seamless, user-friendly platform to browse, order, and access these crucial reagents with greater efficiency.
Strategic Implications of the Partnership
This collaboration represents a significant milestone for both companies. Avantor’s extensive global supply chain and distribution capabilities will ensure that TriLink’s high-performance nucleic acid products reach a broader audience, addressing the increasing demand for advanced molecular biology tools in EMEA. By leveraging Avantor’s established infrastructure, TriLink can focus on research and development while ensuring a steady and reliable supply of its products to the scientific community.
Becky Buzzeo, Chief Commercial Officer at TriLink, expressed enthusiasm about the partnership, stating:
“This partnership marks an important step in expanding access to our cutting-edge nucleic acid technologies across Europe. By collaborating with a trusted partner like Avantor and leveraging their unmatched distribution network, we can better serve the region’s growing demand for innovative solutions and support the advancement of life-changing therapeutic research.”
TriLink’s Commitment to Innovation in Nucleic Acid Therapeutics
TriLink remains dedicated to advancing nucleic acid therapeutics, vaccines, and diagnostics by providing its customers with the highest quality reagents, advanced chemistry solutions, and comprehensive Contract Development and Manufacturing Organization (CDMO) services. The company’s continually expanding portfolio includes award-winning innovations such as CleanCap® M6, a next-generation mRNA capping analog that has been widely recognized for its role in improving mRNA stability and translational efficiency.
Beyond its product offerings, TriLink also provides scalable solutions for mRNA synthesis, oligonucleotide development, and enzyme production, making it a preferred partner for researchers and biopharmaceutical developers worldwide. The company’s robust expertise in nucleic acid synthesis, coupled with its ability to manufacture at GMP-grade levels, ensures that it remains at the forefront of biopharmaceutical innovation.
Impact on the Biotech Industry
The growing focus on mRNA-based therapies and nucleic acid-based drug development has underscored the need for reliable, high-quality reagents. With this partnership, researchers and developers in the EMEA region will have improved access to the materials necessary for groundbreaking research in gene therapy, vaccine development, and personalized medicine.
Moreover, this collaboration aligns with broader industry trends emphasizing the importance of strong supply chains and strategic partnerships to accelerate biopharmaceutical advancements. By combining Avantor’s logistics expertise with TriLink’s scientific leadership, this partnership is poised to have a transformative impact on the biotechnology landscape in EMEA.